Using exhaled breath, we identify bio-markers that correlates to respiratory diseases for patient identification and condition monitoring.
Respire Diagnostics has a vision that measurements of the concentration of biomarkers in exhaled breath will be the next generation of medical diagnostic tool. It is a non-invasive, instantaneous and inexpensive way of quantifying a patients' condition which fulfils the unmet need in a growing market.
Exhaled breath condensate (EBC) analysis has garnered interest for its potential to address the unmet needs for a non-invasive, instantaneous and inexpensive way method of diagnosis. The concentration of biomarkers in EBC has a proven correlation to respiratory diseases and provides a quantitative insight into the user’s respiratory health. Our product aims to bridge the gaps in the market by creating a robust and portable device that integrates both the collection and analysis of EBC.
The market segment that we are targeting is patients with chronic obstructive pulmonary disease (COPD). It is a non-reversible, long term lung-related condition estimated to affect 384 million globally and is set to become the third leading cause of death by 2020. The annual direct cost of COPD to NHS is £800 million per annum, where more than 70% of the direct cost is due to exacerbation. This stems from the lack of a robust and reliable monitoring method as measurements could only be done by clinicians and provide indeterminate results.
Our solution comprises of a handheld device and disposable sensors, suitable for home usage. The user exhales into the device where their breath is condensed and subsequently analysed. The process is completed within five minutes and provides a quantifiable method of evaluating the current condition of their respiratory system, and necessary measures could then be taken. Our device could also be used to tackle unmet clinical needs by identifying patients suspected with COPD, as well as monitoring the efficacy of treatments for known patients.
Exchange of gases at the alveoli during respiration releases water vapour, volatile and non-volatile molecules into the exhaled breath. The concentration of compounds in EBC reflects the metabolic activity in the body.
The concentration of biomarkers in EBC has a correlation to various diseases, thus EBC analysis could provide quantitative insights to the user’s health. This principle has been demonstrated through several pieces of literature that documented the difference in concentration of H2O2 in EBC between healthy and COPD subjects as a notable example. This approach to studying the respiratory system is still in its infancy and devices in the market currently separates the collection and the analysing platform.
Respire Diagnostics aims to bridge the gaps in the market by creating a robust and portable device that integrates both the collection and analysis of EBC.
Get in Touch
36 Churchway, London,